Discovery of MTA-Cooperative PRMT5 Inhibitors for the Treatment of MTAP-Deleted Cancer.

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5•MTA complex and target M...Подробнее

discovery of MRTX1719 for cancer indications - drug annotationsПодробнее

IDE397: a novel MAT2A inhibitor in patients with solid tumors harboring MTAP deletionsПодробнее

Gould: PRMT5 Inhibitors for Hematologic CancerПодробнее

discovery of MAK683, a PRC2 inhibitor - drug annotationsПодробнее

Exploiting Methylthioadenosine Phosphorylase Deficiency in CancerПодробнее

Discovery of Synthetic Lethal Paralog Pairs in the Human Genome | Phoebe ParrishПодробнее

Synthetic Lethality in Cancer Therapeutics - OICR MondaysПодробнее

Sanger Seminar - Functional genomic approaches to guide cancer drug discovery - Dr Mathew GarnettПодробнее

Drug Combinations for Synthetic Lethal Interactions | Protocol PreviewПодробнее

Second-line treatment of mHSPCПодробнее

Protein Methyltransferase Inhibitors as Personalized Cancer TherapeuticsПодробнее

CRISPR screens to identify novel DNA repair defects synthetic lethal therapiesПодробнее

PARP-inhibitors: A New Generation of Cancer DrugsПодробнее

Highlights in lung cancer at ESMO 2022Подробнее

MTAP Loss in Metastatic Breast Cancer Patients: Genomic Landscape | OncotargetПодробнее

The Role of Targeting DNA Repair with PARPПодробнее

IDEAYA (Stock: IDYA) Investor DayПодробнее